TT-816 is under clinical development by Teon Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TT-816’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TT-816 overview

TT-816 is under development for the treatment of solid tumor, non-small cell lung cancer, ovarian cancer and renal cell carcinoma. It is administered through oral route. The drug candidate acts by targeting CB2R, immune checkpoint from G protein-coupled receptor family.

Teon Therapeutics overview

Teon Therapeutics, is a biopharmaceutical company that discovers and develops small molecule drugs for cancer immunotherapy, cardiovascular and metabolic diseases. The company is headquartered in United States.

For a complete picture of TT-816’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.